Agex therapeutics, inc. (AGE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
REVENUES:
Total revenues

515

549

411

380

388

313

380

464

239

Cost of sales

34

79

49

53

63

180

-4

79

109

Gross profit

481

470

362

327

325

133

384

385

130

OPERATING EXPENSES:
Research and development

1,603

1,469

1,447

1,650

1,338

1,523

1,332

1,384

1,591

Acquired in-process research and development

-

-

-

-

-

0

0

0

800

General and administrative

2,073

1,717

2,194

2,119

2,109

1,968

1,254

1,135

1,290

Total operating expenses

-3,676

-10,724

-3,641

3,769

-3,447

-15,891

-2,586

2,519

3,681

Loss from operations

-3,195

-2,716

-3,279

-3,442

-3,122

-3,358

-2,202

-2,134

-3,551

OTHER INCOME/(EXPENSES):
Interest income (expense), net

-52

-24

8

33

12

32

39

27

18

Other income (expense), net

25

-

-

-

-28

-

-

-

-

Gain on sale of equity method investment in Ascendance

-

-

-

-

-

0

0

0

3,215

Other expense, net

-

-

-

-

-

-

-

-

3

Other income, net

-

-

48

257

-

-

-22

156

-

Total other income (expense), net

-27

-7

56

290

-16

84

17

183

3,230

NET LOSS BEFORE INCOME TAXES

-3,222

-2,723

-3,223

-3,152

-3,138

-3,274

-2,185

-1,951

-321

Income tax provision

-

18

54

3

73

-

-

-

-

NET LOSS

-3,222

-2,741

-3,277

-3,155

-3,211

-3,274

-2,185

-1,951

-321

Net loss attributable to noncontrolling interest

-35

-30

-56

-66

-78

-88

-34

-21

-86

NET LOSS ATTRIBUTABLE TO AGEX

-3,187

-2,711

-3,221

-3,089

-3,133

-3,186

-2,151

-1,930

-235

NET LOSS PER COMMON SHARE: BASIC AND DILUTED

-0.08

-0.07

-0.09

-0.08

-0.09

-0.08

-0.06

-0.06

-0.01

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED

37

111,380

37

37,630

36

71,645

35

34,225

33,750

Subscription and Advertisement Revenues [Member]
Total revenues

338

340

342

305

345

282

373

333

239

Grant Revenues [Member]
Total revenues

86

77

41

47

15

-

-

-

-

Other Revenues [Member]
Total revenues

91

132

28

28

28

-

7

131

-